HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nobili, F. Articles by Darcourt, J. Search for Related Content PubMed PubMed Citation Articles by Nobili, F. Articles by Darcourt, J.

Brain Perfusion Follow-Up in Alzheimer’s Patients During Treatment with Acetylcholinesterase Inhibitors

¹ Clinical Neurophysiology, Department of Internal Medicine, University of Genoa, Genoa, Italy
² Nuclear Medicine Department, Laboratory of Biophysics, Centre Antoine Lacassagne, University of Nice, Sophia Antipolis, France
³ Nuclear Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
⁴ Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom
⁵ Department of Physiopathology, University of Florence, Florence, Italy
⁶ Memory Center, Federation of Clinical Neuroscience, CHU-University of Nice, Sophia Antipolis, France

Transient cognitive and behavioral stabilization of patients with Alzheimer’s disease (AD) is the main goal of long-term acetylcholinesterase inhibitor (AChEI) therapy, but response to treatment is variable and, indeed, only some of the patients are stabilized. This is usually assessed by means of clinical and neuropsychologic scales, whereas functional neuroimaging could allow objective evaluation of the topographic correlates of the effect of therapy on brain functioning. The aim of this study was to evaluate brain perfusion changes by SPECT in AD patients during chronic AChEI therapy in relation to their cognitive evolution. Methods: Forty-seven consecutive outpatients with mild-to-moderate probable AD (as defined by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association and the Diagnostic and Statistical Manual of Mental Disorders [4th edition criteria] and a score of 15 on the Mini-Mental State Examination [MMSE]) were enrolled in 2 centers over a 1-y period and underwent SPECT with ^99mTc-hexamethylpropyleneamine oxime at the time of enrollment (t₀). All of them started AChEI therapy. Nine patients were lost at follow-up, and drugs were withdrawn from 3 patients. Of the remaining 35 patients, who received regular AChEI therapy (donepezil, 5 or 10 mg/d; rivastigmine, 6 or 9 mg/d) throughout the observation period, only the 31 patients receiving donepezil were considered to avoid the possible confounding effect of different drugs. The 31 patients completed the study and a second SPECT examination was performed 15.0 ± 3.0 mo later (t₁). They were divided into stabilized (17 patients) and nonstabilized (14 patients) subgroups on the basis of the minimum expected annual rate of decline of the MMSE score, derived from a meta-analysis of the literature. SPECT data were analyzed by means of statistical parametric mapping. Results: At baseline, the stabilized and nonstabilized patients were comparable for age, sex distribution, education, MMSE scores, memory impairment (selective reminding test [SRT]), apolipoprotein E genotype, AChEI dose regimen, and SPECT findings. The SRT scores decreased significantly (P < 0.01) in the nonstabilized subgroup but not in the stabilized subgroup. No significant difference was found between the baseline and repeated SPECT data in the stabilized subgroup. In contrast, in the nonstabilized subgroup a significant perfusion reduction was found in the frontal, temporal, and parietal superficial cortex and in the occipital precuneus in the right hemisphere and in the frontal and mesial temporal cortex in the left hemisphere. On repeated SPECT, regional cerebral blood flow was significantly lower in a left frontal region in the nonstabilized group than in the stabilized group. Conclusion: The regional cerebral blood flow decreases in several cortical regions in AD patients with cognitive deterioration despite long-term AChEI therapy, similar to that observed in untreated patients, whereas it remains stable in AD patients with stabilized cognitive performance during therapy.

Key Words: SPECT • regional cerebral blood flow • Alzheimer’s disease • acetylcholinesterase inhibitors • donepezil

This article has been cited by other articles:

				H. Matsuda Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT J. Nucl. Med., August 1, 2007; 48(8): 1289 - 1300. [Abstract] [Full Text] [PDF]

				H. Engler, A. Forsberg, O. Almkvist, G. Blomquist, E. Larsson, I. Savitcheva, A. Wall, A. Ringheim, B. Langstrom, and A. Nordberg Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain, November 1, 2006; 129(11): 2856 - 2866. [Abstract] [Full Text] [PDF]

				J. A. H. R. Claassen and R. W. M. M. Jansen Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2006; 61(3): 267 - 271. [Abstract] [Full Text] [PDF]

				M. S. Mega, I. D. Dinov, V. Porter, G. Chow, E. Reback, P. Davoodi, S. M. O'Connor, M. F. Carter, H. Amezcua, and J. L. Cummings Metabolic Patterns Associated With the Clinical Response to Galantamine Therapy: A Fludeoxyglucose F 18 Positron Emission Tomographic Study Arch Neurol, May 1, 2005; 62(5): 721 - 728. [Abstract] [Full Text] [PDF]

				A. J. Saykin, H. A. Wishart, L. A. Rabin, L. A. Flashman, T. L. McHugh, A. C. Mamourian, and R. B. Santulli Cholinergic enhancement of frontal lobe activity in mild cognitive impairment Brain, July 1, 2004; 127(7): 1574 - 1583. [Abstract] [Full Text] [PDF]

				L Mosconi, B Nacmias, S Sorbi, M T R De Cristofaro, M Fayazz, A Tedde, L Bracco, K Herholz, and A Pupi Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, March 1, 2004; 75(3): 370 - 376. [Abstract] [Full Text] [PDF]

				G B Frisoni, P h Scheltens, S Galluzzi, F M Nobili, N C Fox, P H Robert, H Soininen, L-O Wahlund, G Waldemar, and E Salmon Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC J. Neurol. Neurosurg. Psychiatry, October 1, 2003; 74(10): 1371 - 1381. [Abstract] [Full Text] [PDF]

				A. Noda, H. Takamatsu, N. Matsuoka, S. Koyama, H. Tsukada, and S. Nishimura Effect of N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide Monohydrate (FK960), an Antidementia Drug with a Novel Mechanism of Action, on Regional Cerebral Blood Flow and Glucose Metabolism in Aged Rhesus Macaques Studied with Positron Emission Tomography J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 213 - 217. [Abstract] [Full Text] [PDF]

				C. L. Grady, A. R. McIntosh, S. Beig, M. L. Keightley, H. Burian, and S. E. Black Evidence from Functional Neuroimaging of a Compensatory Prefrontal Network in Alzheimer's Disease J. Neurosci., February 1, 2003; 23(3): 986 - 993. [Abstract] [Full Text] [PDF]